Advances in the treatment of primary central nervous system lymphoma

VernacularTitle:原发性中枢神经系统淋巴瘤的治疗进展
Author: Pengchao ZHOU ¹ ; Xiaoyi WANG ; Jie YU
Author Information

1. 滨州医学院研究生院,山东烟台 264003
Keywords: primary central nervous system lymphoma; methotrexate; new drugs
From: Journal of Shenyang Medical College 2024;26(3):304-308
CountryChina
Language:Chinese
Abstract: Primary central nervous system lymphoma(PCNSL)is an aggressive extranodal non-Hodgkin's lymphoma involving cerebrospinal fluid,medulla spinalis,intraocular structures,cranial nerves,and pia.It is an infiltrating malignant tumor with no involvement outside the central nervous system.PCNSL is sensitive to radiotherapy and chemotherapy,and treatment includes high-dose methotrexate-based remission induction,surgery and consolidation therapy with whole-brain radiotherapy.In recent years,some new drugs,including Bruton tyrosine kinase inhibitor,programmed cell death protein-1 inhibitor,lenalidomide,rituximab,pemetrexed,chimeric antigen receptor T-cell immunotherapy and selective inhibitor of nuclear export,have entered clinical trials or use stage and shown good therapeutic effect.This article reviews the traditional treatment programs of PCNSL patients and summarizes the latest progress of treatment.